Treatment of recurrent malignant gliomas by surgery combined with recombinant adenovirus-p53 injection.
- Author:
Jian-xin ZHU
1
;
Zhong-min LI
;
Feng-yang GENG
;
Qiang FU
;
Chuan-jun GUO
;
Yi-lei XIAO
;
Zhi-ti ZHANG
;
Gang LI
Author Information
- Publication Type:Clinical Trial
- MeSH: Adenoviridae; genetics; Adult; Brain Neoplasms; pathology; surgery; therapy; Combined Modality Therapy; Female; Follow-Up Studies; Genes, p53; Genetic Therapy; Glioma; pathology; surgery; therapy; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Recombinant Proteins; therapeutic use; Survival Rate; Tumor Suppressor Protein p53; genetics; therapeutic use
- From: Chinese Journal of Oncology 2010;32(9):709-712
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the efficacy and toxicity of combination therapy with surgery and recombinant adenovirus-p53 injection of recurrent malignant gliomas.
METHODS38 patients with recurrent malignant gliomas were included in this study. Among them, 18 patients of combined treatment group had Ommaya reservoirs placed into the tumor cavities after the resection of the tumors and received regular recombinant adenovirus-p53 injections after the operation. The other 20 patients received surgery alone.
RESULTSThe 6-month and 1-year survival rates after the combination therapy were 66.7% (14/18) and 44.4% (8/18), respectively. The median survival time was 9.7 months. Compared with the surgery-alone group, the combined treatment group achieved significant improvement (P < 0.05). The Karnofsky score was significantly improved at 6 months after the combination therapy compared with that before the treatment (P < 0.05).
CONCLUSIONThe recombinant adenovirus-p53 injection is safe and effective in treatment of recurrent malignant gliomas. The combination therapy of surgery and recombinant adenovirus-p53 injection may improve the life quality and the prognosis in patients with recurrent malignant gliomas.
